4/A//SEC Filing
TYSON TIMOTHY 4/A
Accession 0001209191-23-025002
CIK 0001556263other
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 4:41 PM ET
Size
29.0 KB
Accession
0001209191-23-025002
Insider Transaction Report
Form 4/AAmended
TYSON TIMOTHY
Director
Transactions
- Award
Common Stock
2022-09-16+8,000→ 8,000 total - Award
Stock Option (right to buy)
2022-09-16+3,286→ 3,286 totalExercise: $66.18Exp: 2028-05-24→ Common Stock (3,286 underlying) - Award
Stock Option (right to buy)
2022-09-16+2,191→ 2,191 totalExercise: $26.93Exp: 2029-08-22→ Common Stock (2,191 underlying) - Award
Stock Option (right to buy)
2022-09-16+2,848→ 2,848 totalExercise: $27.84Exp: 2030-08-19→ Common Stock (2,848 underlying) - Award
Stock Option (right to buy)
2022-09-16+3,856→ 3,856 totalExercise: $25.10Exp: 2031-08-23→ Common Stock (3,856 underlying) - Award
Common Stock
2022-09-16+257→ 8,257 total - Award
Stock Option (right to buy)
2022-09-16+12,000→ 12,000 totalExercise: $7.35Exp: 2032-09-15→ Common Stock (12,000 underlying) - Award
Stock Option (right to buy)
2022-09-16+2,232→ 2,232 totalExercise: $93.56Exp: 2022-11-21→ Common Stock (2,232 underlying) - Award
Stock Option (right to buy)
2022-09-16+1,094→ 1,094 totalExercise: $199.68Exp: 2026-05-09→ Common Stock (1,094 underlying) - Award
Stock Option (right to buy)
2022-09-16+2,191→ 2,191 totalExercise: $53.17Exp: 2028-08-26→ Common Stock (2,191 underlying) - Award
Stock Option (right to buy)
2022-09-16+3,856→ 3,856 totalExercise: $7.07Exp: 2032-08-23→ Common Stock (3,856 underlying)
Footnotes (10)
- [F1]Acquired pursuant to the merger agreement between the issuer and Tyme Technologies, Inc. ("Tyme") in exchange for 5,865 shares of Tyme common stock having a market value of $0.3086 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
- [F10]This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $0.31 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F2]The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
- [F3]This option is fully vested and replaced an option to purchase 50,058 shares of Tyme common stock at an exercise price of $4.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F4]This option is fully vested and replaced an option to purchase 25,000 shares of Tyme common stock at an exercise price of $8.75 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F5]This option is fully vested and replaced an option to purchase 75,000 shares of Tyme common stock at an exercise price of $2.90 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F6]This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $2.33 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F7]This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $1.18 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F8]This option is fully vested and replaced an option to purchase 65,000 shares of Tyme common stock at an exercise price of $1.22 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
- [F9]This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $1.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001207405
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 19, 8:00 PM ET
- Accepted
- Apr 20, 4:41 PM ET
- Size
- 29.0 KB